Most labs don’t need to prove they can make peptides. They need dependable material that keeps peptide research moving without tying up people and instruments. The call between in-house work and outsourcing rests on how often you need peptides and what proof your results must stand on.
Clarify the four options before you compare costs
Labs often talk about this as an either-or call, but there are really four paths, and they aren’t interchangeable. A crude bench product is not the same as a purified powder with batch paperwork. That’s a different product.
In-house solid-phase synthesis
In-house work means your own staff runs solid-phase peptide synthesis on your own instrument. Most labs doing this work use Fmoc chemistry, though a smaller set keeps t-Boc capability for cases where its deprotection approach fits their approved setup and safety controls.
You set the queue and can remake a short test peptide without raising a purchase order, but you also own upkeep and reagent stocks. Waste leaves through approved lab channels with manifests and trained handlers.
This path gives you control over timing for small exploratory changes. It also puts failed runs squarely on your team. When a synthesis aggregates on resin, your staff spends the time troubleshooting it.
Institutional core facility
A core facility sits between bench work and a commercial order. You submit a sequence and the core staff runs synthesis on shared instruments. Purification and mass confirmation are often available in the same building through adjacent systems.
You don’t maintain the synthesizer and don’t stock every monomer, but you do work within the core queue and its method set. That trade can work well when your own volume is too low to justify a dedicated instrument but too steady to send everything out.
Core staff see many sequences across groups, and that breadth can help when your design hits a familiar snag. You still need to plan around shared calendars and user fees that vary by service tier.
Commercial custom synthesis
A custom provider makes a peptide to your requested sequence and scale. You send the sequence and purity request, and the provider sources building blocks and returns lyophilized material with analysis.
This path fits one-off difficult builds and larger screening sets that would tie up your synthesizer and staff. You avoid stocking rare monomers for a single project, but you give up day-to-day control over the run and rely on the provider’s review process.
Quotes differ in what they bundle. Some combine purification and analysis; others list them as separate lines. Read the scope rather than assuming two quotes describe the same deliverable.
Catalogue purchase for standard items
Catalogue purchase is different from custom work. You buy an existing research compound that a supplier already has characterized and stocked. There is no synthesis queue for your sequence, because the item exists.
You get batch paperwork with the vial and can reorder the same code for repeat assays. This path only works when a standard item matches your study need. It does not cover novel sequences or unusual modifications that require a fresh build.
For controls and reference peptides that are already available, catalogue stock can avoid the wait for a new synthesis. Confirm stock status and the analytical specification before planning around delivery. Your team can then spend time on assays rather than on synthesis setup and cleanup.
Ask how often you really need peptides
Volume decides a lot. A lab that designs new sequences each week has a different equation than a lab that needs a handful of controls each year. Be honest about your real throughput over the past year, not your hoped-for throughput.
If your team iterates constantly on short analogs, bench access can pay off, since you can test and retest without waiting on external queues. If your needs are sporadic, fixed costs work against you.
Reagents have storage requirements and usable lifetimes that must be tracked even during quiet periods. An instrument that sits idle still needs maintenance, and operators may need refresher training before returning to a demanding run.
Projected demand can look steadier than it really is, especially when a grant or new project is still taking shape. A realistic count of sequences and resyntheses gives a clearer base for the cost math that follows.
Count resyntheses as well as new designs. Failed runs still consume staff time and reagents, and controls and standards add to the total even when they feel routine. Shared projects across groups can lift volume enough to justify bench capacity. Low and uneven demand points toward outside sourcing.
Don’t base the call on one busy month. Look at a full year of orders and bench runs, including the weeks when no one needed a peptide, because those weeks still carry service contracts and storage costs.
Available capacity matters as much as raw demand. A single-channel system with one trained user is easily blocked by leave or by a long difficult run. If your assays can’t pause, you need a backup source even when bench volume looks healthy.
Count the full cost of doing it yourself
Reagent price per residue tells only part of the story. The full bench cost has labor and waste and upkeep built in. Miss those parts and in-house always looks cheap on paper.
Start with people and time. Someone prepares the run and monitors coupling efficiency. Someone repeats failed couplings and cleans the system. That time is not free even when salaries are already covered, and it pulls staff from cell work and assays that directly support your program.
Then add materials and waste. Amino acid building blocks and resins cost money whether the run works or not. Repeat couplings use extra equivalents. Solvent waste leaves through approved streams with fees and paperwork, and filters and columns wear out with use.
Instruments add another layer. A synthesizer needs service and replacement parts. Purification needs prep HPLC time and mass confirmation needs LC-MS time. Many labs cover those needs through a core facility rather than buying both systems, but that access still has queue time and user fees that belong in your math.
There’s also safety overhead. Fmoc work still needs ventilation and approved handling for solvents and cleavage mixes. Training and waste logs take staff hours that rarely show up in per-peptide quotes, and your institution may require specific approvals for acid handling and waste accumulation areas.
Storage and records add quiet costs too. Building blocks need tracked inventory and cold storage where specified. Batch notes must be kept in a form others can audit later. When those habits slip, repeat work becomes harder and publication review becomes slower.
Evaluate outside help, from core facilities to catalogue sources
Outside help isn’t one thing. Each source solves a different problem, so match the source to the need before you compare quotes.
For custom work, read the quote for what is actually included. Desalting alone is not the same as HPLC purification. Prep-scale purification with mass confirmation costs more because it uses more instrument time and review. Ask how batch-to-batch consistency is checked when you will need the same peptide for repeat assays.
Pricing policies also differ. Some providers have academic or repeat-order terms; others charge separately for resynthesis when purity falls short. Get those terms in writing so a failed batch doesn’t stall your project and force a redesign.
Turnaround planning should focus on usable product rather than crude output. A fast crude batch still needs purification, drying and review before it can go into assays. A slower quote that delivers purified and lyophilized powder on a stated schedule may let you plan cell work with fewer gaps.
What catalogue purchase covers
A search for “peptides Canada” can introduce domestic catalogue options; assess each against the required compound specification and batch documentation. Catalogue items come with a lot code and analysis that you can file with your study records. These products are sold for research use and are not for human or veterinary use. A domestic address can make shipping and direct communication simpler when you have questions about reconstitution and storage.
Reordering the same catalogue code helps with repeat assays, though you still check each new lot code against your acceptance limits. That habit matters for publication-grade data where reviewers may ask for purity and identity proof.
Catalogue sourcing does not replace custom synthesis. It covers cases where a standard sequence and purity grade already fit your protocol. When your design calls for a new sequence, you’re back to choosing between bench, core and custom build routes.
Read purity paperwork like a reviewer will
Purity is one place where comparisons can go wrong. A low price means little if purity does not meet your assay need, and yield alone does not establish what is in the vial. Identity, content and assay-specific quality requirements belong in the same assessment.
Ask for HPLC data and mass data together. HPLC gives an estimate of purity under stated conditions. Mass data supports molecular mass, but it does not by itself prove sequence or rule out all impurities. You need both traces plus method notes to judge what you have.
That’s why the Certificate of Analysis matters. A useful CoA lists identity and purity, names methods and gives a lot code. Compare each new lot to your limits before you run key assays, and file the paperwork where the whole team can find it months later.
Don’t accept a single number without context. Purity depends on column and detection settings. A percentage without gradient and wavelength details can’t be compared across vendors. Look for chromatograms with baselines you can actually read.
Salt form and final format deserve the same attention. A lyophilized powder can contain counterions and water that affect weighing and buffer compatibility. Request net peptide content where accurate concentration matters, and read its definition alongside purity: content can include peptide impurities and is not a measure of pure target fraction. Record the calculation basis so assay concentrations are comparable across lots.
Keep retention samples where practical and maintain records when your program may publish or transfer methods. Reviewers and collaborators may ask how material quality was assessed. A tidy file of CoAs with lot codes saves time when those questions arrive late in review.
Let sequence difficulty and library size guide the call
Not all sequences behave the same in SPPS. Coupling efficiency drops when chains aggregate or fold on resin. Hydrophobic stretches and beta-sheet-prone motifs are known trouble spots that demand closer method control.
Length adds pressure, but there is no single cutoff that fits all chemistries. A medium-length peptide with a sticky core can be harder than a longer but well-behaved chain. Some labs use microwave-assisted protocols for such cases; others adjust coupling reagents and times with standard heating. Success depends on experience and method control on both sides of the make-or-buy line.
Difficult builds also consume more reagents through repeats, and that changes cost math quickly. A sequence that needs double couplings and extended washes ties up instrument time, and it generates more solvent waste that must leave through approved channels.
Libraries change the math again. A screening set of dozens of related peptides needs parallel capacity. Running those builds one by one on a single-channel bench instrument ties up staff. A core or custom provider with parallel lines can handle that load while your team stays on assays.
There’s no shame in splitting the work. Make the easy analogs where you have control and place the hard builds where capacity exists. That split keeps momentum when one difficult member would otherwise block the whole set.
Usable-product turnaround matters more than crude cycle time for libraries. Plan when each member must be purified and checked relative to its screening slot. Staggered delivery can work if it fits the study design and comes with clear lot paperwork; other screens may require the complete set before work starts.
Build a hybrid workflow that holds up
A mixed workflow can suit groups with varied peptide needs, but it is not automatically the best answer for every lab. Keep short exploratory builds in-house when volume and expertise justify the upkeep. Send out complex builds and large libraries when external capacity better meets your analytical and throughput needs. Use catalogue stock when an existing item fits so you don’t remake what is already available.
Write down your rules so choices stay consistent. For a request intended for clinical use, involve your institution’s quality and regulatory specialists to define the applicable manufacturing, testing and traceability requirements. Discovery research material cannot be assumed suitable for administration. A project moving toward translation does not make every exploratory assay a GMP activity, but future requirements should shape planning early.
Review the mix each year as projects shift, since volume and sequence mix change faster than instruments depreciate.
You don’t advance a program by proving you can run SPPS. You advance it with clean material and records that others can repeat.